Amendment to the Claims:

This listing of claims will replace all previous versions and listings of claims in the application:

1-22. (Canceled)

23. (Currently amended) A method for identifying tumor cells as responsive to treatment with an antibody inhibiting the association of HER2 with another member of the ErbB receptor family comprising:

(a) providing a biological sample comprising HER2-positive tumor cells; ~~and~~

(b) ~~detecting~~ determining the level of phosphorylation of an ErbB receptor in said biological sample~~,~~ ; and ~~wherein said phosphorylation indicates that said tumor cells are responsive to treatment with said antibody~~

(c) identifying said HER2-positive tumor cells as responsive to treatment with said antibody if a significant level of phosphorylation is determined.

24. (Currently amended) The method of claim 23 wherein the level of phosphorylation of an ErbB2 (HER2) receptor is ~~detected~~ determined.

25. (Previously presented) The method of claim 23 wherein the other member is selected from the group consisting of HER3, HER1 and HER4.

26. (Previously presented) The method of claim 23 wherein the antibody binds HER2.

27. (Previously presented) The method of claim 26 wherein the anti-HER2 antibody blocks ligand activation of an ErbB heterodimer comprising HER2.

28. (Previously presented) The method of claim 27 wherein the antibody is rhuMAb 2C4.

29-39. (Canceled)

40. (Previously presented) The method of claim 23 wherein the biological sample is tissue obtained from a tumor biopsy.

41. (Previously presented) The method of claim 23 wherein the biological sample is a biological fluid comprising circulating tumor cells and/or circulating plasma proteins.

42. (Previously presented) The method of claim 23 wherein the tumor is selected from the group consisting of breast cancer, prostate cancer, lung cancer, colorectal cancer and ovarian cancer.

43. (Currently amended) The method of claim 23 wherein the level of ErbB receptor phosphorylation is determined by immunoprecipitation of the ErbB receptor and Western blot analysis.

44. (Currently amended) The method of claim 43 wherein the level of ErbB receptor phosphorylation is indicated by the presence of a phospho-ErbB receptor band on the gel.

45. (Previously presented) The method of claim 43 further comprising the step of confirming ErbB receptor phosphorylation by immunohistochemistry using a phospho-specific anti-ErbB receptor antibody.

46. (Currently amended) The method of claim 23 wherein the level of ErbB receptor phosphorylation is determined by immunohistochemistry.

47. (Currently amended) A method for predicting the response of a subject diagnosed with a HER2-positive tumor to treatment with an antibody inhibiting the association of HER2 with another member of the ErbB receptor family comprising:

(a) providing a biological sample obtained from said subject, comprising HER2-positive tumor cells; ~~and~~;

(b) ~~detecting~~ determining the level of phosphorylation of an ErbB receptor in said biological sample~~,~~; and

~~wherein said phosphorylation indicates that said patient is likely to respond to treatment with said antibody~~

(c) predicting that said subject is likely to respond to treatment with said antibody, if a significant level of phosphorylation is determined.

48. (Previously presented) The method of claim 47 wherein said ErbB receptor is ErbB2 (HER2).

49. (Previously presented) The method of claim 47 wherein the other member is selected from the group consisting of HER3, HER1 and HER4.

50. (Previously presented) The method of claim 47 wherein the antibody binds HER2.

51. (Previously presented) The method of claim 50 wherein the anti-HER2 antibody blocks ligand activation of an ErbB heterodimer comprising HER2.

52. (Previously presented) The method of claim 51 wherein the antibody is rhuMAb 2C4.

53-63. (Canceled)

64. (Previously presented) The method of claim 47 wherein the biological sample is tissue obtained from a tumor biopsy.

65. (Previously presented) The method of claim 47 wherein the biological sample is a biological fluid comprising circulating tumor cells and/or circulating plasma proteins.

66. (Previously presented) The method of claim 47 wherein the tumor is selected from the group consisting of breast cancer, prostate cancer, lung cancer, colorectal cancer and ovarian cancer.

67. (Currently amended) The method of claim 47 wherein the level of ErbB receptor phosphorylation is determined by immunoprecipitation of the ErbB receptor and Western blot analysis.

68. (Currently amended) The method of claim 67 wherein the level of ErbB receptor phosphorylation is indicated by the presence of a phospho-ErbB receptor band on the gel.

69. (Previously presented) The method of claim 67 further comprising the step of confirming ErbB receptor phosphorylation by immunohistochemistry using a phospho-specific anti-ErbB receptor antibody.

70. (Currently amended) The method of claim 47 wherein the level of ErbB receptor phosphorylation is determined by immunohistochemistry.

71. (Currently amended) A method for identifying a subject responsive to treatment with an anti-HER2 antibody comprising

a) ~~detecting~~ determining the level of phosphorylation of an ErbB receptor in circulating tumor cells of said subject, and

b) determining that said subject is likely to respond to treatment with an anti-HER2 antibody if a significant level of said phosphorylation is ~~detected~~ determined.

72. (Currently amended) The method of claim 71 wherein ErbB2 (HER2) phosphorylation is ~~detected~~ determined.

73. (Previously presented) The method of claim 72 wherein said subject is a human.

74-88. (Canceled)